| Tekturna (aliskiren) / PDL |
NCT00441064: Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren |
|
|
| Completed | 4 | 132 | US | Aliskiren | Novartis | Hypertension | 11/07 | 11/07 | | |
NCT00654875 / 2007-002469-11: Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. |
|
|
| Completed | 4 | 328 | US, Europe | Aliskiren, Tekturna, Rasilez, Placebo to Aliskiren | Novartis | Essential Hypertension | 11/08 | 11/08 | | |
ATLAAST, NCT00739596: Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans |
|
|
| Completed | 4 | 332 | US | Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks | Novartis Pharmaceuticals | Hypertension | 03/09 | 03/09 | | |
ATTAIN, NCT00772577: Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension |
|
|
| Completed | 4 | 386 | US | Aliskiren Hydrochlorothiazide, Ramipril | Novartis | Hypertension | 03/09 | 03/09 | | |
ACTION, NCT00760266: Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population |
|
|
| Completed | 4 | 451 | US | Aliskiren, Hydrochlorothiazide | Novartis | Hypertension | 04/09 | 04/09 | | |
ALTO, NCT00542269 / 2007-003677-10: Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome |
|
|
| Terminated | 4 | 178 | Europe | Amlodipine, Aliskiren, Ramipril | Novartis | Hypertension With Metabolic Syndrome | 07/09 | 07/09 | | |
| Unknown status | 4 | 30 | Europe | Aliskiren, Rasilez 300mg per day | UMC Utrecht | Chronic Kidney Disease, Hypertension, Muscle Sympathetic Nerve Activity | 07/09 | 01/10 | | |
|
VANTAGE, NCT00809926: 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension |
|
|
| Completed | 4 | 451 | US | Valsartan/aliskiren, Valsartan | Novartis | Stage 2 Hypertension | 07/09 | 07/09 | | |
| Completed | 4 | 256 | Europe | Aliskiren, Hydrochlorothiazide, Amlodipine | Novartis | Essential Hypertension ( Mild to Moderate) | 08/09 | 08/09 | | |
AACESS, NCT00853957: Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension |
|
|
| Completed | 4 | 443 | US | Aliskiren/Amlodipine, Amlodipine | Novartis | Hypertension | 08/09 | 08/09 | | |
NCT00631917: A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension |
|
|
| Completed | 4 | 774 | US, Europe, RoW | Aliskiren, Ramipril, Placebo to Ramipril, Placebo to Aliskiren | Novartis | Hypertension | 09/09 | 09/09 | | |
2007-005256-16: A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in patients with essential hypertension |
|
|
| Completed | 4 | 640 | Europe | Rasilez 150 mg Filmtabletten, Rasilez 300 mg Filmtabletten, Delix 5 mg Tabletten, Ramipril, C09XA02, Tablet, Capsule*, Rasilez 150 mg Filmtabletten, Rasilez 300 mg Filmtabletten, Delix 5 mg Tabletten, Delix protect 10 mg Tabletten | Novartis Pharma Services AG, Novartis Farmacéutica, S.A. | Essential hypertension | | | | |
AIMS, NCT00797316: Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension |
|
|
| Completed | 4 | 532 | US | Aliskiren, Hydrochlorothiazide | Novartis | Hypertension | 12/09 | 12/09 | | |
NCT01048047: Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients |
|
|
| Unknown status | 4 | 88 | Europe | aliskiren/amlodipine | University of Pavia | Hypertension | 12/09 | 03/10 | | |
ASTRIDE, NCT00787605: Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus |
|
|
| Completed | 4 | 860 | US | Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren | Novartis | Hypertension, Diabetes Mellitus | 01/10 | 01/10 | | |
ASCENT, NCT00942994: Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension |
|
|
| Completed | 4 | 412 | US | Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ) | Novartis | Hypertension | 03/10 | | | |
NCT01038895: Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria |
|
|
| Unknown status | 4 | 120 | Europe | Ramipril, Experimental | University of Pavia | Hypertension, Type 2 Diabetes | 03/10 | 06/11 | | |
| Completed | 4 | 822 | Canada, Europe, RoW | Aliskiren, Telmisartan, Placebo to Aliskiren, Placebo to Telmisartan | Novartis | Hypertension | 06/10 | 06/10 | | |
ACADEMY, NCT01070030: Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension |
|
|
| Completed | 4 | 230 | RoW | Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day) | Novartis | Stage II Hypertension | 10/10 | 10/10 | | |
NCT01095822: Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics |
|
|
| Unknown status | 4 | 50 | US | Aliskiren + Valsartan | HeartDrug Research LLC, Novartis | Diabetes Mellitus | 12/10 | 03/11 | | |
| Completed | 4 | 506 | Europe | Aliskiren, Ramipril, Matching placebo to Aliskiren, Matching placebo to Ramipril | Novartis | Essential Hypertension | 01/11 | 01/11 | | |
ViVID, NCT00927394: Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus |
|
|
| Completed | 4 | 1143 | US | Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan | Novartis | Hypertension | 10/11 | 10/11 | | |
ANDROMEDA, NCT01056731: A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. |
|
|
| Completed | 4 | 253 | RoW | Aliskiren and HCTZ | Novartis | High Blood Pressure | 10/11 | 10/11 | | |
REALITY, NCT01060865: Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements |
|
|
| Terminated | 4 | 50 | RoW | Aliskiren, Blood Pressure, Ambulatory Blood Pressure monitor, Self measured home blood pressure | Meir Medical Center, Novartis Pharmaceuticals | Blood Pressure, High | 10/11 | 12/11 | | |
NCT00974922: Vitamin D Deficiency in Patients With Hypertension |
|
|
| Terminated | 4 | 40 | US | Aliskiren, Tekturna, Cholecalciferol, Vitamin D3, Placebo | UConn Health, Novartis | Vitamin D Deficiency, Hypertension | 12/11 | 12/11 | | |
NCT03115853: The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function |
|
|
| Completed | 4 | 31 | US | Aliskiren 150 mg, Tekturna, Placebo, HCTZ, Aliskiren 300 mg | Vanderbilt University Medical Center | High Blood Pressure | 01/12 | 01/12 | | |
NCT01349114: Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects |
|
|
| Terminated | 4 | 21 | US | aliskiren 300 mg once daily, Tekturna, Placebo/sugar pill | University of Alabama at Birmingham, Novartis | Diabetes, Pre-hypertension, Hypertension | 01/12 | 01/12 | | |
| Completed | 4 | 32 | Europe | Aliskiren, Brand name: Ralisez, ATC-code: C09XA02, Moxonidine, No brand name (generic product), ATC-code: C02AC05, Hydrochlorothiazide, ATC-code: C03AA03, Placebo (for aliskiren), Placebo (for moxonidine and hydrochlorothiazide) | UMC Utrecht, Novartis Pharmaceuticals | Hypertension, Abdominal Obesity, Metabolic Syndrome | 02/12 | 02/12 | | |
NCT01284114: Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients |
|
|
| Completed | 4 | 23 | Japan | Aliskiren, Direct renin inhibitor | Jichi Medical University | Hypertension, Chronic Kidney Disease | 05/12 | 05/12 | | |
NCT01394770: Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients |
|
|
| Unknown status | 4 | 350 | Europe | Aliskiren, Rasilez, Norvasc | University of Campania "Luigi Vanvitelli", IRCCS San Raffaele | Hypertension, Dialysis | 09/12 | 09/12 | | |
| Unknown status | 4 | 350 | NA | aliskiren | University of Campania "Luigi Vanvitelli", IRCCS San Raffaele | Hypertension, End Stage Renal Disease | 09/12 | 09/12 | | |
NCT01570686 / 2011-005297-36: 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension |
|
|
| Completed | 4 | 589 | US, Canada, Europe, RoW | Aliskiren, Tekturna, rasilez | Novartis Pharmaceuticals | Hypertension | 11/12 | 11/12 | | |
NCT00994253: Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics |
|
|
| Withdrawn | 4 | 0 | US | Aliskiren, Tekturna, Hydrochlorothiazide, HCTZ | William Beaumont Hospitals, Novartis Pharmaceuticals | Hypertension, Diabetes Type 2 | 12/12 | 12/12 | | |
NCT01235910: Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation |
|
|
| Terminated | 4 | 1 | US | Aliskiren, Tekturna (aliskiren), Neoral (cyclosporine) | University of Colorado, Denver, American Heart Association | Hypertension, Cardiac Transplantation | 12/12 | 12/12 | | |
NCT01184599: A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy |
|
|
| Unknown status | 4 | 30 | Japan | aliskiren | Kagawa University | Glomerulonephritis, IGA, Hypertension | 03/13 | | | |
| Completed | 4 | 74 | Europe | Aliskiren, Rasilez, Losartan, Amlodipine, Hydrochlorothiazide (HCTZ) | Novartis Pharmaceuticals | Hypertension, Left Ventricle Hypertrophy | 04/13 | 04/13 | | |
NCT01409408: Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan |
|
|
| Withdrawn | 4 | 0 | RoW | Aliskiren, Rasilez., Amlodipine, Norvasc. | Hospital Universitario Pedro Ernesto, Novartis | Hypertension, Diabetes Mellitus | 04/13 | 12/13 | | |
| Unknown status | 4 | 92 | US | Vitamin D (cholecalciferol), Tekturna (Aliskirin), cholecalciferol, Tekturna(Aliskiren) plus placebo | Wayne State University, Novartis | Hypertension | 07/13 | 03/14 | | |
| Completed | 4 | 237 | Japan | Aliskiren, any angiotensin receptor blockers | Shiga University | Type 2 Diabetes Mellitus, Hypertension | 08/14 | 12/14 | | |
NCT01519635: Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension |
|
|
| Completed | 4 | 24 | Europe | Aliskiren, Rasilez, Hydrochlorothiazide, Esidrex | Centre Hospitalier Universitaire Vaudois | Hypertension | 10/14 | 10/14 | | |
2008-003568-20: Renin Genotype and Response to Renin Angiotensin System Blockade. |
|
|
| Completed | 4 | 100 | Europe | Rasilez, Coversyl 10 mg, Atacand, Istin 10mg, Rasilez, Coversyl 10 mg, Atacand, Istin 10mg | Prof Alice Stanton | Hypertension | | 06/11 | | |
2009-015600-26: An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension |
|
|
| | 4 | 12 | Europe | Rasilez, Rasilez | Universitätsklinikum Würzburg, Universitätsklinikum Würzburg | Determination of the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension. | | | | |
2009-016738-28: Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension |
|
|
| Completed | 4 | 40 | Europe | Film-coated tablet, Tablet | AZIENDA OSPEDALIERA PISANA | essential hypertension | | | | |
2011-002587-24: Effect of Aliskiren drug in patients with high blood pressure Effetto del farmaco Aliskiren in pazienti con pressione alta |
|
|
| Ongoing | 4 | 42 | Europe | ENALAPRIL S.G.*28CPR 5MG, RASILEZ*56CPR RIV 150MG, ENALAPRIL S.G.*28CPR 5MG, RASILEZ*56CPR RIV 150MG | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, Novartis | dysfunction of coronary microcirculation in arterial hypertension disfunzione del microcircolo coronarico nell\'ipertensione arteriosa | | | | |
2012-000250-55: Renin-Angiotensin System Quantification in patients treated with specific medication against hypertension (Aliskiren or Candesartan) |
|
|
| Completed | 4 | 24 | Europe | Film-coated tablet, Tablet, Rasilez, Atacand | Medizinische Universität Wien, Universitätsklinik für innere Medizin III | - Chronic kidney disease stages III-IV (defined by MDRD formula)- Hypertension, - Chronic kidney disease stages III-IV (defined by MDRD formula)- Hypertension, Body processes [G] - Physiological processes [G07] | | | | |
| Completed | 4 | 24 | Europe | RAS blockade discontinuation, Aliskiren, Rasilez, Candesartan, Atacand | Medical University of Vienna | Hypertension, Chronic Kidney Disease, Proteinuria | 02/16 | 02/16 | | |
| Withdrawn | 4 | 0 | US | Aliskiren, Rasilez, Tekturna, Amlodipine, Ramipril, Hydrochlorothiazide | Novartis Pharmaceuticals | Hypertension | 06/18 | 06/18 | | |
ChiCTR1900028215: Treatment of Obstructive Sleep Apnea Syndrome Related Hypertension with Aliskiren (Rasilez): a Single Center, One-Armed, Open-Label Clinical Trial. |
|
|
| Recruiting | 4 | 30 | | Aliskiren | Beijing Anzhen Hospital, Capital Medical University; Beijing Anzhen Hospital, Zhaoke Pharmaceutical (Hefei) Co. Ltd. | Hypertension in Obstructive Sleep Apnea Syndrome(OSAS) patients | | | | |
